Sun Pharma rises 3.5%

about 6 years ago
No image

The moment the market opened for trading, Sun Pharma rose 3.5% at Rs.521.90; after that it slipped and is now trading at Rs.512 levels, up some 1.5%. Its 52-week high is at Rs.709.80 and low at Rs.433.15.

There was good news for the company – the US FDA granted its approval for the specialty and high margin branded drug, Ilumya which is used for the treatment of moderate-to-severe plaque psoriasis.

Sun Pharma had in-licensed the drug from Merck in September 2014 for an upfront cost of $80 million. The arrangement now is that Merck will manufacture it while Sun Pharma will pay milestones and royalties.

Most of the brokerage houses have put out a report stating that Sun will face very stiff competition for this drug and to gain market share, it might have to offer much better prices.

Popular Comments

No comment posted for this article.